ESGCT 2026 Preview: Gene and Cell Therapy Trends
ESGCT 2026 at a glance ESGCT 2026 will spotlight emerging cell and gene therapy…
AI in Healthcare and Digital Health Today—March 23, 2026
This week’s AI in Healthcare and Digital Health update highlights regulatory…
Healthcare and Pharma Industry Trends H2 2025: From Innovation to Execution
An in-depth analysis of pharma and healthcare industry trends in H2 2025,…
Lucid Diligence Brief: uniQure AMT-191 Fabry dosing pause
Lucid Diligence Brief: uniQure AMT-191 Fabry dosing pause Professional…
Lucid Diligence Brief: Waker BioScience Series A in CGT
Lucid Diligence Brief: Waker BioScience Series A in CGT Professional audiences…
Lucid Diligence Brief: Made Scientific and Cellergy Therapeutics manufacturing partnership to advance CLG-001
Lucid Diligence Brief: Made Scientific and Cellergy Therapeutics manufacturing…
Lucid Diligence Brief: Azalea Therapeutics launches with $82M financing
Lucid Diligence Brief: Azalea Therapeutics launches with $82M financing…
Lucid Diligence Brief: AAVantgarde Bio $141M Series B
Lucid Diligence Brief: AAVantgarde Bio $141M Series B Professional audiences…
Cell and Gene Therapy Clinical Trials 2025 Edition
Introduction Cell and gene therapy (CGT) represents a groundbreaking frontier…
Cell and Gene Therapy Clinical Trials – 2024 Edition
Gene therapy clinical trials promise transformative breakthroughs in treating…
How a leading Biotech company supported its go-/no-go decision in the ophthalmology gene therapy (GT) space through a workshop.
The Challenge: Uncovering perceptions of GT in ophthalmology. LucidQuest…
How we helped a Top-10 BioPharma company enhance its strategic decision-making in the Sickle Cell Disease space.
The challenge: To map the competitive landscape in Cell and Gene Therapy for…